Evaluating 68Ga-FAPI PET/CT for treating advanced liver cancer
The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
Ruijin Hospital · NCT06746194
This study is testing if a special type of imaging can help doctors see how well treatment is working for people with advanced liver cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Ruijin Hospital (other) |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Trial ID | NCT06746194 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of 68Ga-FAPI PET/CT imaging in assessing the response of patients with advanced unresectable hepatocellular carcinoma to systemic antitumor therapy. Participants will undergo PET/CT scans before treatment and after three months of therapy, with their imaging results compared to histopathological findings to determine efficacy. The study aims to enhance the evaluation process for treatment responses in this patient population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with a pathological and clinical diagnosis of advanced unresectable hepatocellular carcinoma.
Not a fit: Patients with serious comorbidities or conditions that may interfere with participation, such as severe organ dysfunction or those who are pregnant, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of treatment response evaluations for patients with advanced liver cancer.
How similar studies have performed: While the use of PET/CT imaging in cancer evaluation is established, the specific application of 68Ga-FAPI in this context is relatively novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Pathological and clinical diagnosis of advanced unresectable hepatocellular carcinoma patients. 2. Signed and dated informed consent form. 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. Aged 18-75 years old. Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction 3. Pregnant women and women who may be pregnant, women who are breastfeeding. 4. Non-compliant person
Where this trial is running
Shanghai, Shanghai Municipality
- Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine — Shanghai, Shanghai Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Jiajia Hu
- Email: jiajiahu@shsmu.edu.cn
- Phone: 13524945287
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Hepatocellular Carcinoma, hepatocellular carcinoma, 68Ga-FAPI, PET/CT